# A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

> **NCT05920876** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** QLS32015

## Key facts

- **NCT ID:** NCT05920876
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920876, "A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05920876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*